Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.47 |
| ▸ | PDE4A | P27815 | 2/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13060217 | 0.91 | GPR119 (0.44) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL14624556 | 0.85 | PDE4D (0.50) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL13060447 | 0.83 | PDE4D (0.49) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL13060192 | 0.83 | PDE4D (0.48) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL13060448 | 0.82 | PDE4D (0.50) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL13060218 | 0.80 | GPR119 (0.36) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL13588430 | 0.78 | KDM1A (0.45) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL13003964 | 0.78 | CNR2 (0.32) | — | |
| SCHEMBL13003974 | 0.77 | BCL9 (0.33) | GPR119 | |
| SCHEMBL28909021 | 0.77 | GPR119 (0.53) | GPR119PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846946-B2 | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING PLOUGH CORPORATION (US) | 2010-12-07 | — | — | US | disclosed |
| US-7635705-B2 | treating allergy-induced airway responses, congestion, obesity, metabolic syndrome, alcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma and cognition deficit disorders; histamine H3 antagonists | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-20090286830-A1 | HETEROATOM-LINKED SUBSTITUTED PIPERIDINES AND DERIVATIVES THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS | SCHERING CORPORATION | 2009-11-19 | — | — | US | disclosed |
| US-20070015807-A1 | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
| WO-2007001975-A1 | PIPERIDINE DERIVATIVES USEFUL AS HISTAMINE H3 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015807-A1 | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | HRH3, HRH4, CHRM2 | GPR119 44/4885PDE4D 4824/4885PDE4B 4732/4885 |
| US-20090286830-A1 | HETEROATOM-LINKED SUBSTITUTED PIPERIDINES AND DERIVATIVES THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS | HRH3, HRH4, CHRM2 | GPR119 44/4885PDE4D 4824/4885PDE4B 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.